Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Álvarez Sabín, M. Alonso de Leciñana, J. Gállego, A. Gil Peralta, I. Casado, J. Castillo, et al.
Plan de atención sanitaria al ictus.
Neurología, 21 (2006), pp. 717-726
[2.]
B. Fuentes, E. Díez-Tejedor.
Stroke Units. Many questions, some answers.
Int J Stroke, 4 (2009), pp. 28-37
[3.]
J. Masjuan.
Unidades de ictus: el mejor tratamiento para los pacientes con ictus.
Neurología, 24 (2009), pp. 285-287
[4.]
M. Rodríguez-Yáñez, J. Álvarez-Sabín, E. Díez-Tejedor, J. Castillo, por el Comité SITS-MOST España.
Tratamiento trombolítico en el ictus isquémico agudo en España: experiencia del registro SITS (Safe Implementation of Thrombolysis in Stroke).
Neurología, 24 (2009), pp. 288-291
[5.]
A. Cruz-Culebras, A. García-Pastor, G. Reig, B. Fuentes, P. Simal, J.C. Méndez-Cendón, et al.
Intervencionismo neurovascular en la fase aguda del infarto cerebral.
Neurologían, 25 (2010), pp. 279-286
[6.]
J.L. Saver.
Intra-arterial fibrinolysis for acute ischemic stroke: the message of melt.
Stroke, 38 (2007), pp. 2627-2628
[7.]
C. Castaño, L. Dorado, C. Guerrero, M. Millán, M. Gomis, N. Pérez de la Ossa, et al.
Mechanical thrombectomy with the solitaire AB device in large artery occlusions of the anterior circulation: a pilot study.
Stroke, 41 (2010), pp. 1836-1840
[8.]
D.L. Bhatt, K.A. Fox, W. Hacke, P.B. Berger, H.R. Black, W.E. Boden, et al.
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
N Eng J Med, 354 (2006), pp. 1706-1717
[9.]
R.L. Sacco, H.C. Diener, S. Yusuf, D. Cotton, S. Ounpuu, W.A. Lawton, et al.
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
N Eng J Med, 359 (2006), pp. 1238-1251
[10.]
H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, M. Kaste, et al.
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial.
Lancet, 364 (2004), pp. 331-337
[11.]
S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, et al.
Dabigatran versus warfarin in patients with atrial fibrillation.
N Eng J Med, 361 (2009), pp. 1139-1151
[12.]
H.C. Diener, S.J. Connolly, M.D. Ezekowitz, L. Wallentin, P.A. Reilly, S. Yang, RE-LY study group, et al.
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
Lancet Neurol, 9 (2010), pp. 1157-1163
[13.]
A. Gil Núñez.
Advances in the prevention of cerebral ischaemia due to atrial fibrillation.
Neurologia, 25 (2010), pp. 401-408
[14.]
C. Medi, G.J. Hankey, S.B. Freedman.
Stroke risk and antithrombotic strategies in atrial fibrillation.
Stroke, 41 (2010), pp. 2705-2713
[15.]
A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schottewn, I. Savelieva, S. Ernst, European Heart Rhythm Association, et al.
European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
Eur Heart J, 31 (2010), pp. 2369-2429
[16.]
R.G. Hart, L.A. Pearce, M.I. Aguilar.
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
Ann Intern Med, 146 (2007), pp. 857-867
[17.]
M.N. Levine, G. Raskob, S. Landefeld, C. Kearon.
Hemorrhagic complications of anticoagulant treatment.
Chest, 119 (2001), pp. 108S-121S
[18.]
H.D. White, M. Gruber, J. Feyzi, S. Kaatz, H.F. Tse, S. Husted, et al.
Comparisons of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results from SPORTIF III and V.
Arc Inter Med, 167 (2007), pp. 239-245
Copyright © 2012. Sociedad Española de Neurología
